Home / Treatments / Anti-Psychotic
Anti-Psychotic denials: what the review data shows
Independent reviewers have decided 33 published cases where an insurer denied Anti-Psychotic — and they overturned the insurer 39.4% of the time. A denial for Anti-Psychotic is a starting position, not a final answer.
Published decisions
33
2001–2026
Overturned
39.4%
13 denials reversed
Conditions behind anti-psychotic denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Bipolar Disorder | 10 | 30% |
| Depression | 5 | 80% |
| Depression - Severe | 4 | 50% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 29 | 41.4% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 4 | 25% |
Typical time to a decision
20 days
Most land between 12 and 21 days
Handled as urgent
30.3%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for esketamine (Spravato) nasal spray. This patient carries a documented diagnosis of major depressive disorder, recurrent severe, without psychosis. Moreover, the patient meets the definition of treatment resistant major depressive disorder due to failure of medical therapies including high-dose Paxil 40 mg and Lexapro. He has also had multiple trials of sufficient duration with Wellbutrin. Currently, he is on Viibryd 40 mg daily in addition to Wellbutrin XL 300 mg daily and BuSpar 5 mg three times a day. He is currently on the maximum dose of Viibryd, and has undergone a sufficient trial of medication and Wellbutrin.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The parents of the patient requested authorization and coverage for risperidone and aripiprazole.Risperidone and aripiprazole are currently the only medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of irritability associated with autism spectrum disorder (ASD) in children and adolescents. Further, patients with ASD are frequently treated with multiple medications. Clinical trials have found these medications to be effective in reducing irritability consisting primarily of physical aggression and severe tantrum behaviors, as well as repetitive behaviors in ASD. Risperidone has been approved for ages 5 through 16 years and aripiprazole for ages 6 – through 17.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for (1) risperidone (Risperdal), and (2) inpatient psychiatric hospitalization services for a minimum of 30 days and up to 90 days at a facility that specializes in paranoid schizophrenia with negative affect and bipolar disorder. In treating patients with psychosis, the determination of the antipsychotic and treatment plan should be in a shared decision making model between the patient and the clinical team. In this case, the patient has been noncompliant with and resistant to taking medications. Given that the patient’s current psychiatric treatment team is not recommending treatment with risperidone and the patient’s refusal of medications, the requested medication is not medically indicated.
Nature of Statutory Criteria/Case Summary: The parent of an enrollee has requested authorization and coverage for the medication oxcarbazepine.Findings: Three out of three physician reviewers found that the requested medication oxcarbazepine is not likely to be more beneficial than any other available standard treatments for the patient’s medical condition.According to the International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder, the anticonvulsants divalproex sodium and carbamazepine have not fared well head-to-head with second-generation antipsychotics (SGAs). The Task Force report noted that in two meta-analyses, treatment effect was less robust with anticonvulsants than with SGAs.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Anti-Psychoticwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.